Abstract Number: 2456 • ACR Convergence 2025
Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Background/Purpose: The Definition Of Remission in SLE (DORIS) criteria were developed to align SLE remission definitions.1,2 Post hoc analyses of clinical trial data demonstrated that…Abstract Number: 2290 • ACR Convergence 2025
Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
Background/Purpose: Assessing clinical improvements in Sjögren's Disease (SjD) is challenging. Our objective was to describe patterns of improvement in SjD using ESSDAI and ESSPRI indices…Abstract Number: 1831 • ACR Convergence 2025
Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Background/Purpose: : Systemic Lupus Erythematosus (SLE) follows a characteristic relapsing-remitting course with unpredictable flares interspersed with periods of relative quiescence. Mycophenolate mofetil (MMF) has emerged…Abstract Number: 1491 • ACR Convergence 2025
Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
Background/Purpose: The concept of disease modification (DM) has been recently introduced to improve the long-term care of patients (pts) with SLE. DM is defined as…Abstract Number: 1318 • ACR Convergence 2025
Diagnostic Delay in Rheumatoid Arthritis and its Impact on Radiographic Outcomes: A Systematic Review and Meta-analysis of 100,066 Patients
Background/Purpose: Timely diagnosis is the cornerstone of effective rheumatoid arthritis (RA) management, with early treatment shown to significantly improve outcomes through a treat-to-target strategy. While…Abstract Number: 0900 • ACR Convergence 2025
Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitides (AAV) are a heterogenous group systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels requiring prompt initiation of immunosuppressive treatment…Abstract Number: 0514 • ACR Convergence 2025
Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Background/Purpose: Blood immunophenotyping reveals systemic immune alterations and therapeutically actionable molecular endotypes in Sjögren’s Disease (SjD). Reported changes include reduced memory B cells, plasmacytoid dendritic…Abstract Number: 0439 • ACR Convergence 2025
Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort
Background/Purpose: Despite advances in therapeutic strategies, a subset of patients with rheumatoid arthritis (RA) continues to experience persistent symptoms. In 2022, the EULAR proposed a…Abstract Number: 0191 • ACR Convergence 2025
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…Abstract Number: 2430 • ACR Convergence 2025
Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
Background/Purpose: Mechanisms driving cognitive impairment (CI) in systemic lupus erythematosus (SLE) remain poorly understood; conflicting results exist regarding the relationship between CI and disease activity.…Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…Abstract Number: 1472 • ACR Convergence 2025
Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort
Background/Purpose: LLDAS is a desirable state in lupus, with ongoing global reports on its durability and outcomes. The relationship between LLDAS, baseline characteristics, and drug…Abstract Number: 1317 • ACR Convergence 2025
The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
Background/Purpose: Insomnia and rheumatoid arthritis (RA) are caught in a snowball effect, where chronic pain disrupts sleep and causes poor sleep quality, which in turn…Abstract Number: 0580 • ACR Convergence 2025
Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Background/Purpose: Psoriatic arthritis (PsA) is a chronic disease that causes inflammation of the joints, entheses, spine, skin, and nails.1 While available advanced treatments (txs) for…
ACR Meeting Abstracts